CTLA-4 inhibitors, such as ipilimumab, have been approved for the treatment of melanoma, and combinations of PD-1 and CTLA-4 inhibitors are being investigated for the treatment of several types of cancer. The gene discussed is CTLA4; the disease is melanoma.